Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2012 3
2013 3
2014 10
2015 8
2016 11
2017 10
2018 6
2019 14
2020 18
2021 20
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

98 results
Results by year
Filters applied: . Clear all
Page 1
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ. Cortellini A, et al. Among authors: rijavec e. J Immunother Cancer. 2021 Apr;9(4):e002421. doi: 10.1136/jitc-2021-002421. J Immunother Cancer. 2021. PMID: 33827906 Free PMC article.
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG, Filiberti RA, Alama A, Orengo AM, Mussap M, Coco S, Vanni I, Boccardo S, Rijavec E, Genova C, Biello F, Barletta G, Rossi G, Tagliamento M, Maggioni C, Grossi F. Dal Bello MG, et al. Among authors: rijavec e. J Transl Med. 2019 Mar 8;17(1):74. doi: 10.1186/s12967-019-1828-0. J Transl Med. 2019. PMID: 30849967 Free PMC article.
Metabolic disorders and the risk of cholangiocarcinoma.
Ghidini M, Ramai D, Facciorusso A, Singh J, Tai W, Rijavec E, Galassi B, Grossi F, Indini A. Ghidini M, et al. Among authors: rijavec e. Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):999-1007. doi: 10.1080/17474124.2021.1946393. Epub 2021 Aug 21. Expert Rev Gastroenterol Hepatol. 2021. PMID: 34423721 Review.
Advances in treatment of mesothelioma.
Maggioni C, Barletta G, Rijavec E, Biello F, Gualco E, Grossi F. Maggioni C, et al. Among authors: rijavec e. Expert Opin Pharmacother. 2016 Jun;17(9):1197-205. doi: 10.1080/14656566.2016.1176145. Epub 2016 Apr 21. Expert Opin Pharmacother. 2016. PMID: 27055148 Review.
Hematopoietic growth factors in lung cancer.
Genova C, Rijavec E, Grossi F. Genova C, et al. Among authors: rijavec e. Curr Opin Oncol. 2016 Mar;28(2):135-44. doi: 10.1097/CCO.0000000000000268. Curr Opin Oncol. 2016. PMID: 26742020 Review.
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, Genova C. Tagliamento M, et al. Among authors: rijavec e. Expert Opin Biol Ther. 2018 Jul;18(7):829-835. doi: 10.1080/14712598.2018.1492539. Epub 2018 Jul 4. Expert Opin Biol Ther. 2018. PMID: 29936901 Review.
98 results